Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

Ear and hearing·2026
Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
Same author

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.

Cancer communications (London, England)·2026
Same author

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

Cancer chemotherapy and pharmacology·2026
Same author

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Nov 15, 2025

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.6K

Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing

Jeannine S McCune1, Arjen M Punt2, Rosa F Yeh3

  • 1Department of Hematologic Malignancies Translational Sciences, Beckman Research Institute at City of Hope, Duarte, California.

Therapeutic Drug Monitoring
|March 6, 2021
PubMed
Summary
This summary is machine-generated.

A new proficiency testing program was developed for busulfan dosing in hematopoietic cell transplant. Results show variability in busulfan quantitation and dosing, indicating a need for further education and testing to ensure patient safety.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.2K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.0K

Related Experiment Videos

Last Updated: Nov 15, 2025

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.6K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.2K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.0K

Area of Science:

  • Pharmacology
  • Clinical Toxicology
  • Hematopoietic Stem Cell Transplantation

Background:

  • Personalized busulfan dosing is crucial for improving efficacy and reducing toxicity in hematopoietic cell transplant (HCT) conditioning regimens.
  • Existing regional regulations lack standardized interlaboratory comparisons for busulfan concentration monitoring.
  • A novel interlaboratory proficiency program was established to assess busulfan quantitation, pharmacokinetic modeling, and dosing protocols.

Purpose of the Study:

  • To design and implement a proficiency testing program for busulfan analysis and dosing.
  • To evaluate the accuracy of busulfan quantitation and pharmacokinetic modeling across participating laboratories.
  • To identify areas for improvement in busulfan therapeutic drug monitoring and dose recommendations.

Main Methods:

  • Development of a novel busulfan stabilization method for sample transport without dry ice.
  • Participating laboratories analyzed proficiency samples and a theoretical case for pharmacokinetic modeling and dose recommendations.
  • Descriptive statistics were used to evaluate performance, with accuracy defined as ±15% for concentration and ±10% for exposure/dose.

Main Results:

  • Accurate busulfan quantitation (within 85%-115% of reference) ranged from 67% to 85% across proficiency samples.
  • Correct dose recommendations were provided by the majority of participants (88% in round 1, 71% in round 2).
  • The program successfully identified inaccuracies in busulfan quantitation, modeling, and dosing.

Conclusions:

  • A proficiency testing program for busulfan analysis and dosing in HCT recipients has been successfully developed.
  • Proficiency testing revealed variability in laboratory performance, highlighting the need for enhanced educational initiatives.
  • Further interlaboratory proficiency rounds are recommended to ensure optimal and accurate busulfan dosing for improved patient outcomes.